'Cozaar XQ,' an antihypertensive combination drug that contains losartan, may be resupplied to pharmacies within the first quarter of next year, at the earliest.

The company had made preparations to change the API source of Cozaar XQ to be the same as the one for Cozaar, which uses a losartan API from a different overseas manufacturer (France), and explained that it will start manufacturing in December next month to supply the market in the first quarter of 2022.

The company had stopped the shipment of Cozaar XQ after impurities that exceed the standard level were detected in the API of Cozaar XQ during the company’s independent inspections. Currently, the supply of Cozaar XQ 5/50mg, 5/